title: Comparing guidelines for the treatment of inflammatory bowel disease.
abstract: As we enter into the era of 'personalized medicine', many of the recommendations of 'evidence-based medicine' require scrutiny and adaptation to optimize individual outcomes. Several examples of these discrepancies are exemplified by the topics of aminosalicylate use in Crohn's disease, early use of biologic agents that target TNF and the role of calcineurin inhibitors versus anti-TNF agents in steroid-refractory ulcerative colitis.
authors.affiliation: Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medicine, Chicago, Ill., USA.
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Hanauer
authors.forename: Joseph B
authors.initials: JB
authors.lastname: Kirsner
mesh_terms: D010131:Aminosalicylic Acid / Q000627:therapeutic use; D019703:Calcineurin / Q000378:metabolism; D065095:Calcineurin Inhibitors; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D065095:Calcineurin Inhibitors; D004791:Enzyme Inhibitors; D014409:Tumor Necrosis Factor-alpha; D010131:Aminosalicylic Acid; D019703:Calcineurin